1. Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR).
- Author
-
Zehentmayr F, Feurstein P, Ruznic E, Langer B, Grambozov B, Klebermass M, Hüpfel H, Feichtinger J, Minasch D, Heilmann M, Breitfelder B, Steffal C, Gastinger-Grass G, Kirchhammer K, Kazil M, Stranzl H, and Dieckmann K
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Aged, 80 and over, Austria, Adult, Prospective Studies, Neoplasm Staging, Radiotherapy Dosage, Chemoradiotherapy adverse effects, Chemoradiotherapy methods, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung radiotherapy, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms pathology, Lung Neoplasms radiotherapy, Lung Neoplasms mortality, Lung Neoplasms drug therapy, Registries, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal adverse effects, Progression-Free Survival, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Agents, Immunological adverse effects
- Abstract
Background: Chemo-radioimmunotherapy with total radiation doses of 60-66 Gy in 2 Gy fractions is the standard of care for non-small cell lung cancer (NSCLC) UICC stage III. The Austrian radio-oncological lung cancer study association registry (ALLSTAR) is a prospective multicentre registry intended to document clinical practice at the beginning of the Durvalumab era., Patients and Methods: Patients were eligible if they had pathologically verified unresectable NSCLC stage III with a curative treatment option. Chemo-radiation combined with immunotherapy was performed according to local treatment practices. The endpoints were local control (LC), progression-free survival (PFS) and toxicity., Results: Between 2020/03 and 2023/04, 12/14 (86 %) Austrian radiation-oncology centres recruited 188 patients (median 17, range: 1-89). PD-L1 testing was performed in 173/188 (93 %) patients. The median interval between the end of chemoradiotherapy and start of Durvalumab was 14 days (range: 1-65). About 40 % (75/188) of the patients received a total radiation dose of > 66 Gy (range: 67.1-100), which improved 2-year LC (86 % versus 60 %, HR = 0.41; 95 %-CI: 0.17-0.98; log-rank p-value < 0.05). Median PFS for patients with Durvalumab was 25.8 months (95 %-CI: 21.9-not reached) compared to 15.7 months (95 %-CI: 13.2-27.8) for those without (HR = 1.88; 95 %-CI: 1.16-3.05; log-rank p-value < 0.01). The rates of esophageal and pulmonary toxicities were 34.6 % and 23.9 %, respectively, including one case of grade 4 pneumonitis. In the subcohort of 75 patients who received > 66 Gy, 19 (25 %) cases of pulmonary toxicity grades 1-3 were observed., Conclusion: While Durvalumab impacts PFS, LC can be improved by total radiation doses > 66 Gy without excess toxicity., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF